已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Upregulation of immune genes in the proliferative phase endometrium enables classification into women with recurrent pregnancy loss versus controls

子宫内膜 怀孕 月经周期 队列 子宫内膜活检 医学 产科 妇科 队列研究 活检 转录组 男科 生理学 生物 内科学 基因 基因表达 遗传学 激素
作者
Laerke Heidam Juul Andersen,Raquel Martínez,Yifan Dai,Jens Ole Eriksen,Maria K. Gerlach,Lise Grupe Larsen,Nicholas S. Macklon,Kristine Juul Hare,Albin Sandelin,Henriette Svarre Nielsen,Thomas Vauvert F. Hviid
出处
期刊:Human Reproduction [Oxford University Press]
卷期号:40 (6): 1045-1065 被引量:4
标识
DOI:10.1093/humrep/deaf051
摘要

Abstract STUDY QUESTION Does the transcriptome of preconceptional endometrium in the proliferative phase show a specific profile in women with recurrent pregnancy loss (RPL)? SUMMARY ANSWER A specific differential gene expression signature in endometrial samples for women experiencing RPL compared with IVF control women was identified including an RPL subgroup characterized by upregulation of immune-related genes and pathways. WHAT IS KNOWN ALREADY RPL affects 1–3% of couples trying to become parents with both short- and long-term health implications; furthermore, the underlying pathophysiology is complex and heterogeneous with no explanations found for more than half of the couples. Some studies indicate that immunological dysfunction plays a role even preconceptionally and during implantation; however, the few published studies of endometrial transcriptomes from women with RPL have had small sample sizes and focused on the secretory phase of the menstrual cycle. STUDY DESIGN, SIZE, DURATION The study was based on two cohorts of women: an RPL cohort (n = 108) and a control cohort (n = 27). Endometrial samples were collected at two university hospital clinics from March 2013 until February 2019. Dating of the endometrium was made by histological examination by experienced pathologists. PARTICIPANTS/MATERIALS, SETTING, METHODS All women were between 18 and 42 years at the time of collection of the biopsy. RPL was defined as three or more consecutive pregnancy losses or two second-trimester losses or stillbirths. The control group consisted of women referred to IVF/ICSI treatment with a presumed healthy endometrium. All biopsies, except one, were collected in a natural menstrual cycle. In total, 108 women with RPL were subjected to RNA-seq analysis. Seventy-six biopsies were in the proliferative phase, 29 were in the secretory phase, and three could not be classified. For the control women, in total, 27 were included in the RNA-seq analysis; 22 biopsies were in the proliferative phase, one was in the secretory phase, and four could not be classified. Total RNA was extracted from the endometrial biopsies, which had been stored in RNA stabilization solution at −80°C. RNA-seq reads were mapped and quantified using a reference transcriptome and analysed using principal component analysis (PCA), hierarchical clustering, and differential gene expression methods. MAIN RESULTS AND THE ROLE OF CHANCE PCA showed a clear separation of biopsies collected either in the proliferative or secretory phase. For the main analyses, we focused on the women with biopsies in the proliferative phase. PCA and differentially expressed genes (DEGs) revealed that RPL patients were characterized by upregulation of a limited number of immune-related genes and pathways. Further analyses revealed that subjects could describe a gene expression continuum, separable into four different subgroups by the gene expression data, where one subgroup consisted only of IVF controls, one was mixed, and two were composed of RPL patients only. The final analyses showed a distinct subgroup in the RPL cohort with stronger upregulation of immune-related genes, and deconvolution analyses of the bulk RNA-sequencing data together with immunohistochemistry analyses of the CD56 marker indicated an increased number of natural killer cells in this subgroup. A machine-learning model based on the Random Forest algorithm and gene expression data from the 157 DEGs (RPL vs controls) was trained on a subset of the cohort and validated using the remaining subjects, reaching on average 96.6% accuracy (95% CI: 93.3–96.7%), 95.7% sensitivity (95% CI: 95.7–95.7%), and 99.5% specificity (95% CI: 85.7–100.0%). The same analysis using only the most informative genes increased validation accuracies further. LIMITATIONS, REASONS FOR CAUTION The size of the IVF control group and difficulties in defining the most optimal type of control group is a recurrent limitation in this and other RPL studies. Some of the women from the control group might be subfertile in relation to endometrial factors. However, the current control group is a mix of women with different pregnancy and fertility records, which is a strength. Alternative control groups could be women with one to two healthy pregnancies or one to two pregnancy terminations. Furthermore, in only about 10% of the RPL cases information on foetal pathology or chromosomal aneuploidy was obtained. WIDER IMPLICATIONS OF THE FINDINGS The findings presented here indicate that a gene expression signature exists, which can be used to classify RPL patients versus control (non-RPL) women. An interesting aspect is that a pregnancy loss in some women thereby might result in a specific signature detectable as a specific endometrial gene expression profile possibly irrespectively of the cause of the pregnancy loss. Aside from contributing to a further understanding of the pathophysiology and development of new treatments, this finding could lead to a specific and cost-effective test that at an early stage could identify women with high risk of experiencing RPL. To this end, further perspectives include a prospective study, which would explore further utility of the predictive model by analysing endometrial samples collected in the proliferative phase from a cohort of women, who have experienced one pregnancy loss. STUDY FUNDING/COMPETING INTEREST(S) This work was supported by the Region Zealand Health Sciences Research Foundation, Zealand University Hospital through the ReproHealth Research Consortium ZUH, the Frimodt-Heineke Foundation, ‘Direktør Emil C. Hertz og Hustru Inger Hertz’ Fond’, the Torben and Alice Frimodt’s Foundation, the Novo Nordisk Foundation, and the Independent Research Fund Denmark. L.H.J.A., R.S.M., Y.D., K.J.H., H.S.N., A.S., and T.V.F.H. are inventors on a patent application (number EP24171923.6) submitted by Region Zealand, The Capital Region of Denmark, and the University of Copenhagen that covers a diagnostic test based on the results of the study. The authors declared no other competing interests. TRIAL REGISTRATION NUMBER N/A.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3921337477的应助被u114130采纳,获得60
2秒前
搜集达人的应助被哈哈哈采纳,获得10
2秒前
nancyruoxi完成签到,获得积分20
3秒前
zzz完成签到 ,获得积分10
5秒前
姜OMG发布了新的文献求助10
6秒前
Nole的应助被Only2546采纳,获得10
6秒前
8秒前
8秒前
10秒前
mino完成签到 ,获得积分10
11秒前
kali完成签到,获得积分10
14秒前
u114130发布了新的文献求助60
15秒前
王化省发布了新的文献求助10
15秒前
风中睫毛完成签到,获得积分10
16秒前
3921337477的应助被u702150采纳,获得60
19秒前
要早睡的鹏完成签到,获得积分10
20秒前
21秒前
满意的寒凝完成签到 ,获得积分10
22秒前
Maestro_S的应助被晚风采纳,获得10
22秒前
瓜田的猹发布了新的文献求助30
22秒前
xxxmy发布了新的文献求助10
27秒前
钉钉完成签到 ,获得积分10
28秒前
林余发布了新的文献求助10
29秒前
kkk完成签到 ,获得积分10
29秒前
31秒前
u702150发布了新的文献求助60
32秒前
33秒前
yyyyy发布了新的文献求助10
34秒前
3921337477的应助被u484121采纳,获得60
36秒前
寒叶霖完成签到 ,获得积分10
36秒前
舒适沛珊完成签到 ,获得积分10
37秒前
fff发布了新的文献求助10
39秒前
共享精神的应助被xxh采纳,获得10
39秒前
科研通AI6.4的应助被米诺采纳,获得10
40秒前
mondesy1完成签到,获得积分20
40秒前
42秒前
彩色若菱完成签到,获得积分10
44秒前
砰砰完成签到 ,获得积分10
45秒前
秋风完成签到,获得积分0
46秒前
火星上无春完成签到 ,获得积分10
47秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184917
求助须知:如何正确求助?哪些是违规求助? 9573843
关于积分的说明 21833352
捐赠科研通 7782304
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082